C. diff Risk


Oral Bioavailability


Approximate Cost

IV-$9/d PO-$1/d


Dose adjustment not necessary.
Use with caution if CrCl<10mL/minute.

Use with caution in hepatic impairment.

Oral: 10-20mg/kg/DAY given as a single daily dose.

IV: 10mg/kg.DAY given as a single daily dose

Pharyngitis: 12 mg/kg/dose (max: 500mg/dose) once daily x 5 days

PO: 10mg/kg/DAY given as a single dailyt dose on day 1 (max: 500mg/dose), then 5mg/kg/DAY given as a single daily dose on days 2-5 (max: 250mg/dose)

10mg/kg/DAY given as a single daily dose, Max: 500mg/DAY.
Administer IV for at least 2 days then switch to oral.

General Information

Common Usage

Community acquired pneumonia, Pertussis, upper respiratory tract infections, Chlamidial infections, mycobacterial infections, Mycobacterium avium complex (MAC) prophylaxis in HIV patients

Drug Monitoring

Monitor QTc in patients with increased risk.

Adverse Effects

Prolongation of QTc interval.

Major Interactions

While less risk of interaction compared to other macrolides, several potential CYP450 interactions may occur; consult a pharmacist for for more details.

Avoid concurrent use with other drugs that prolong QTc


Antimicrobial class: Macrolide

Average serum half life: pediatrics: 54.5 hours

Route of Elimination: 50% excreted unchanged in bile.

6-14% excreted unchanged in urine.